Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans

被引：12
作者：
Bachli, EB
Vavricka, SR
Walter, RB
Leschinger, MI
Maggiorini, M
机构：
[1] Univ Zurich Hosp, Dept Med, CH-8091 Zurich, Switzerland
[2] Lilly Deutschland GmbH, Dept Med, D-61350 Bad Homburg, Germany
来源：
INTENSIVE CARE MEDICINE | 2003年 / 29卷 / 02期
关键词：
D O I：
10.1007/s00134-002-1605-y
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：337 / 337
页数：1
相关论文
共 3 条
[1]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[2]   Dysfunction of endothelial protein C activation in severe meningococcal sepsis. [J].
Faust, SN ;
Levin, M ;
Harrison, OB ;
Goldin, RD ;
Lockhart, MS ;
Kondaveeti, S ;
Laszik, Z ;
Esmon, CT ;
Heyderman, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :408-416
[3]   Human recombinant activated protein C in meningococcal sepsis [J].
Weisel, G ;
Joyce, D ;
Gudmundsdottir, A ;
Shasby, DM .
CHEST, 2002, 121 (01) :292-295
1